Naoko Takebe to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Naoko Takebe has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
0.630
-
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2024 Feb; 8:e2300371.
Score: 0.201
-
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 03 15; 27(6):1604-1611.
Score: 0.162
-
Notch1 phenotype and clinical stage progression in non-small cell lung cancer. J Hematol Oncol. 2015 Feb 06; 8:9.
Score: 0.108
-
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15.
Score: 0.079
-
Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003 Jan; 9(1):223-7.
Score: 0.047
-
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. PLoS One. 2018; 13(6):e0199361.
Score: 0.034